Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | NR2E1 | Q9Y466 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.41 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6755621 | 0.90 | KMT2A (0.46) | KMT2AMEN1NPC1RAB9ANR2E1 | |
| SCHEMBL6832909 | 0.90 | RAB9A (0.42) | KMT2AMEN1NPC1RAB9ANR2E1 | |
| SCHEMBL6756628 | 0.90 | KMT2A (0.43) | KMT2AMEN1NPC1RAB9ANR2E1 | |
| SCHEMBL6757849 | 0.88 | MAPT (0.48) | KMT2AMEN1NPC1RAB9ANR2E1 | |
| SCHEMBL6803412 | 0.87 | KMT2A (0.39) | KMT2AMEN1NPC1RAB9ANR2E1 | |
| SCHEMBL6756816 | 0.84 | KMT2A (0.47) | KMT2AMEN1NPC1RAB9ANR2E1 | |
| SCHEMBL6808666 | 0.83 | NR2E1 (0.56) | KMT2AMEN1NR2E1MAPTGRM5 | |
| SCHEMBL6809571 | 0.81 | KMT2A (0.49) | KMT2AMEN1NPC1RAB9ANR2E1 | |
| SCHEMBL6805289 | 0.78 | MEN1 (0.42) | KMT2AMEN1NPC1RAB9AMAPT | |
| SCHEMBL6757864 | 0.77 | DHODH (0.40) | KMT2AMEN1RAB9ANR2E1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040266774-A1 | Amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-30 | — | — | US | disclosed |
| US-6770667-B1 | N-((IMIDAZOLYL)-PHENYL)-FLUORENE-1-CARBOXAMIDE DERIVATIVES; 5-HYDROXYTRYPTAMINE (5-HT) ANTAGONISTS; PSYCHOLOGICAL, NERVOUS SYSTEM, EATING, BRAIN AND SLEEP DISORDERS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266774-A1 | Amide compounds | TPH1, HTR1A, HTR5A | KMT2A 2167/4885MEN1 1936/4885NPC1 828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.